Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA.
Paediatr Perinat Epidemiol. 2012 Jul;26 Suppl 1(0 1):36-54. doi: 10.1111/j.1365-3016.2012.01284.x.
Vitamin A (VA) deficiency during pregnancy is common in low-income countries and a growing number of intervention trials have examined the effects of supplementation during pregnancy on maternal, perinatal and infant health outcomes. We systematically reviewed the literature to identify trials isolating the effects of VA or carotenoid supplementation during pregnancy on maternal, fetal, neonatal and early infant health outcomes. Meta-analysis was used to pool effect estimates for outcomes with more than one comparable study. We used GRADE criteria to assess the quality of individual studies and the level of evidence available for each outcome. We identified 23 eligible trials of which 17 had suitable quality for inclusion in meta-analyses. VA or beta-carotene (βC) supplementation during pregnancy did not have a significant overall effect on birthweight indicators, preterm birth, stillbirth, miscarriage or fetal loss. Among HIV-positive women, supplementation was protective against low birthweight (<2.5 kg) [risk ratio (RR) = 0.79 [95% confidence interval (CI) 0.64, 0.99]], but no significant effects on preterm delivery or small-for-gestational age were observed. Pooled analysis of the results of three large randomised trials found no effects of VA supplementation on neonatal/infant mortality, or pregnancy-related maternal mortality (random-effects RR = 0.86 [0.60, 1.24]) although high heterogeneity was observed in the maternal mortality estimate (I(2) = 74%, P = 0.02). VA supplementation during pregnancy was found to improve haemoglobin levels and reduce anaemia risk (<11.0 g/dL) during pregnancy (random-effects RR = 0.81 [0.69, 0.94]), also with high heterogeneity (I(2) = 52%, P = 0.04). We found no effect of VA/βC supplementation on mother-to-child HIV transmission in pooled analysis, although some evidence suggests that it may increase transmission. There is little consistent evidence of benefit of maternal supplementation with VA or βC during pregnancy on maternal or infant mortality. While there may be beneficial effects for certain outcomes, there may also be potential for harm through increased HIV transmission in some populations.
维生素 A(VA)缺乏在低收入国家很常见,越来越多的干预试验研究了孕期补充 VA 或类胡萝卜素对母婴、围产期和婴儿健康结果的影响。我们系统地审查了文献,以确定单独研究孕期补充 VA 或类胡萝卜素对母婴、胎儿、新生儿和婴儿早期健康结果影响的试验。对于具有多个可比研究的结果,我们使用荟萃分析来汇总效应估计值。我们使用 GRADE 标准评估每个研究的质量和每个结果的证据水平。我们确定了 23 项符合条件的试验,其中 17 项试验的质量适合进行荟萃分析。孕期补充 VA 或β-胡萝卜素(βC)对出生体重指标、早产、死产、流产或胎儿丢失没有显著的总体影响。在 HIV 阳性妇女中,补充剂可预防低出生体重(<2.5 公斤)[风险比(RR)=0.79[95%置信区间(CI)0.64, 0.99]],但对早产或小于胎龄儿没有明显影响。对三项大型随机试验结果的汇总分析发现,VA 补充剂对新生儿/婴儿死亡率或与妊娠相关的孕产妇死亡率没有影响(随机效应 RR=0.86[0.60, 1.24]),尽管孕产妇死亡率的估计值存在高度异质性(I²=74%,P=0.02)。孕期补充 VA 被发现可改善血红蛋白水平并降低孕期贫血风险(<11.0 g/dL)(随机效应 RR=0.81[0.69, 0.94]),同样存在高度异质性(I²=52%,P=0.04)。我们在汇总分析中没有发现 VA/βC 补充对母婴 HIV 传播的影响,但有一些证据表明它可能会增加传播。孕期补充 VA 或 βC 对母婴死亡率没有一致的获益证据。虽然某些结果可能有益,但在某些人群中,通过增加 HIV 传播也可能存在潜在危害。